Serialization software player Adents has wrapped up a $13 million round to expand its partnership program in the U.S. and break into new markets.

Bionext has picked up Rhenovia Pharma's cell signaling modeling technology and the R&D team that developed it to form a subsidiary, TheraScape.

Bioclinica has added remote clinical trial technology used by Roche and Johnson & Johnson to its cloud platform.

Genedata has landed a deal with Evotec, continuing a busy 18-month period in which it has signed up Bayer, Boehringer Ingelheim and Merck KGaA.

Forentis Fund has committed $7.5 million to Blueprint Bio, a firm focused on identifying, validating and marketing biomarkers.

Mount Sinai has reported a jump in enrollment in a Phase III trial of a Bayer drug after it used natural language processing to sift through EHRs.

Microsoft and Median Technologies have teamed up to develop a cloud computing-powered image analysis technology capable of detecting cancer early.

Pfizer has signed up to use clinical trial technologies from Oracle, a company it has stuck with as its Big Pharma peers have defected to Medidata.